234. Peroxisomal disease (except Adrenoleukodystrophy) Clinical trials / Disease details

Clinical trials : 39 / Drugs : 35 - (DrugBank : 12) / Drug target genes : 13 - Drug target pathways : 45

20 trials found

diseases per page:

Showing 1 to 10 of 20 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04125472 (ClinicalTrials.gov)	June 2, 2021	10/10/2019	Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1	Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1	Primary Hyperoxaluria	Drug: Lumasiran	Alnylam Pharmaceuticals	NULL	Approved for marketing	N/A	N/A	All			Belgium;Canada;France;French Polynesia;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;Un ...
2	EUCTR2019-001346-17-IT (EUCTR)	14/05/2021	07/06/2021	A Phase 3 study of an Investigational Drug, Lumasiran(ALN-GO1) in patients with advanced primary hyp ...	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: [ALN-GO1] INN or Proposed INN: Lumasiran	ALNYLAM PHARMACEUTICALS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 3	United Arab Emirates;United States;Lebanon;Turkey;Israel;United Kingdom;Switzerland;Italy;India;Egyp ...
3	EUCTR2019-001346-17-GB (EUCTR)	22/01/2020	23/07/2019	A Phase 3 study of an Investigational Drug, Lumasiran(ALN-GO1) in patients with advanced primary hyp ...	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: Lumasiran	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	16	Phase 3	United Arab Emirates;United States;Lebanon;Turkey;Israel;United Kingdom;Switzerland;India;Egypt;Fran ...
4	NCT04152200 (ClinicalTrials.gov)	January 21, 2020	31/10/2019	A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ...	Primary Hyperoxaluria Type 1;Primary Hyperoxaluria	Drug: Lumasiran	Alnylam Pharmaceuticals	NULL	Active, not recruiting	N/A	N/A	All	21	Phase 3	United States;Australia;Belgium;France;Israel;Italy;Jordan;Lebanon;Netherlands;Turkey;United Arab Em ...
5	EUCTR2019-001346-17-NL (EUCTR)	05/12/2019	22/08/2019	A Phase 3 study of an Investigational Drug, Lumasiran(ALN-GO1) in patients with advanced primary hyp ...	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: LUMASIRAN	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	16	Phase 3	United States;United Arab Emirates;Lebanon;Turkey;Israel;Switzerland;United Kingdom;India;Egypt;Fran ...
6	EUCTR2019-001346-17-BE (EUCTR)	07/10/2019	21/08/2019	A Phase 3 study of an Investigational Drug, Lumasiran(ALN-GO1) in patients with advanced primary hyp ...	ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: LUMASIRAN	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	16	Phase 3	United States;Egypt;United Kingdom;United Arab Emirates;Switzerland;India;Lebanon;Netherlands;Turkey ...
7	EUCTR2018-004014-17-DE (EUCTR)	23/04/2019	27/12/2018	A Study of an Investigational Drug, Lumasiran(ALN-GO1) in Infants and Young Children with Primary Hy ...	ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacody ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: LUMASIRAN	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 3	France;United States;Israel;Germany;United Kingdom
8	NCT03905694 (ClinicalTrials.gov)	April 22, 2019	1/4/2019	A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1	ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacody ...	Primary Hyperoxaluria;Primary Hyperoxaluria Type 1 (PH1)	Drug: Lumasiran	Alnylam Pharmaceuticals	NULL	Active, not recruiting	0 Years	5 Years	All	18	Phase 3	United States;France;Germany;Israel;United Kingdom
9	EUCTR2018-001981-40-NL (EUCTR)	21/03/2019	21/01/2019	A Phase 3 Study of an Investigational Drug, Lumasiran(ALN-GO1) with an Extended Dosing Period in Chi ...	ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study with an Extended Dosing P ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: lumasiran	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 3	France;United States;United Arab Emirates;Jordan;Israel;Germany;Netherlands;United Kingdom;Japan;Swi ...
10	EUCTR2018-004014-17-GB (EUCTR)	01/03/2019	19/12/2018	A Study of an Investigational Drug, Lumasiran(ALN-GO1) in Infants and Young Children with Primary Hy ...	ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacody ...	Primary Hyperoxaluria Type 1 (PH1) MedDRA version: 20.1;Level: PT;Classification code 10020703;Term: ...	Product Name: lumasiran Product Code: ALN-GO1 INN or Proposed INN: LUMASIRAN	Alnylam Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;United States;Israel;Germany;United Kingdom

First Previous1 2Next Last